Search clinical trials for: CDC-501

Total 5692 results

Assiut University

Not yet recruiting

Immune Markers in Pediatric ITP on Second Line Therapy

ITP - Immune Thrombocytopenia
Celgene

Completed

CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

Neurofibromatosis Type 1 | Recurrent Childhood Pilocytic Astrocytoma | Recurrent Childhood Visual Pathway Glioma

United States, Canada, Australia, New Zealand
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission

Secondary Acute Myeloid Leukemia | Alkylating Agent-Related Acute Myeloid Leukemia

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Terminated

Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Adult Acute Myeloid Leukemia in Remission

United States
National Cancer Institute (NCI)

Withdrawn

Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma

Fatigue | Weight Loss | Fever | Splenomegaly | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1... and other conditions

United States
Washington University School of Medicine
National Cancer Institute (NCI); The Foundation for Barnes-Jewish Hospital; Celldex...

Terminated

Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients

Pancreatic Cancer | Pancreas Cancer | Cancer of the Pancreas

United States
National Cancer Institute (NCI)

Completed

Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Waldenstrom... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Chase Pharmaceuticals Corporation, an affiliate...

Completed

A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia

Alzheimer's Disease

United States
Curis, Inc.

Completed

A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors

Tumors

United States
Chase Pharmaceuticals Corporation, an affiliate...

Completed

Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07

Dementia of the Alzheimer's Type

United States
Celldex Therapeutics

Completed

A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers

Healthy

United States
Genentech, Inc.

Completed

A Study of the Hedgehog Pathway Inhibitor GDC-0449 in Healthy Female Subjects of Non-Childbearing Potential

Healthy
Zhujiang Hospital

Recruiting

Comparison Capsule Sparing Cystectomy and Radical Cystoprostatectomy in Men With Bladder Cancer

Bladder Cancer

China
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell... and other conditions

United States
Assistance Publique - Hôpitaux de Paris

Completed

Injection of CD4 and CD8 + T Cells Anti-Cytomegalovirus (CMV) or Anti-adenovirus (CTLantiCMV)

Cytomegalovirus Infections | Adenovirus Infections

France
Terns, Inc.

Completed

DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis

NASH - Nonalcoholic Steatohepatitis

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Completed

Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia

Anemia | Chronic Myelomonocytic Leukemia | Adult Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Completed

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma | Recurrent B-Cell Prolymphocytic Leukemia | Refractory B-Cell Prolymphocytic Leukemia

United States
Chase Therapeutics Corporation

Active, not recruiting

A Study in Patients With Major Depressive Disorder

Major Depressive Disorder (MDD)

United States
Brian Jonas
National Cancer Institute (NCI); Celgene; Pharmacyclics LLC.

Completed

Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome

Previously Treated Myelodysplastic Syndrome | Myelodysplastic Syndrome | Therapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma | Light Chain Deposition Disease

United States, Puerto Rico, Ireland
M.D. Anderson Cancer Center

Active, not recruiting

Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma

Smoldering Plasma Cell Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Refractory Small Lymphocytic Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory... and other conditions

United States
Roswell Park Cancer Institute
GlaxoSmithKline

Recruiting

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI); Novartis Pharmaceuticals

Completed

Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Brian Lally

Completed

Cytochlor, Tetrahydrouridine, and External-Beam Radiation Therapy in Treating Patients With Cancer That Has Spread to the Brain

Brain and Central Nervous System Tumors

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Plasma Cell Myeloma | Hematopoietic Cell Transplantation Recipient

United States
Hookipa Biotech GmbH

Not yet recruiting

Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART

Human Immunodeficiency Virus (HIV) Infection

United States
NewG Lab Pharma

Active, not recruiting

KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma | Fibrolamellar Carcinoma

Korea, Republic of
Beth Christian
Genentech, Inc.; Celgene

Active, not recruiting

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Burkitt Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Burkitt Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Fatigue | Thrombocytopenia | Fever | Chronic Lymphocytic Leukemia | Lymphadenopathy | Small Lymphocytic Lymphoma | Hypogammaglobulinemia | Lymphocytosis | Night Sweats | Paraproteinemia

United States
Celldex Therapeutics

Terminated

A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs

Chronic Lymphocytic Leukemia (CLL) | Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS) | Acute Myelogenous Leukemia (AML) | Chronic Myelogenous Leukemia (CML) | Non-Hodgkins Lymphoma (NHL) | For Donors | Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling | For Recipients and other conditions

United States
Fox Chase Cancer Center
Knowledge Networks

Completed

Trial of Print Messages to Support the Role of Partners in Promoting Provider Discussions About Prostate Cancer Screening Among AA Men

Prostate Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis

Stage 0 Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Monoclonal B-Cell Lymphocytosis | Stage I Small Lymphocytic Lymphoma

United States
Ashutosh Kumar Tewari

Recruiting

The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting. (PGV-Prostate)

Prostate Cancer

United States
BiondVax Pharmaceuticals ltd.

Completed

A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001)

Healthy

Israel
Johns Hopkins University

Completed

Clinical Practice Guidelines Versus Decision-support for Latent Tuberculosis Infection (LTBI) Management

Latent Tuberculosis

United States
National Cancer Institute (NCI)

Completed

Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer (ADCC)

Recurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Laryngeal Squamous Cell... and other conditions

United States
Joseph Tuscano
National Cancer Institute (NCI); Celgene

Active, not recruiting

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Hairy Cell Leukemia | Refractory Mantle Cell Lymphoma | Recurrent... and other conditions

United States
Essen Biotech

Not yet recruiting

Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells (BAH246)

T Cell Lymphoma | T Cell Prolymphocytic Leukemia | T-cell Acute Lymphoblastic Leukemia | T Cell Leukemia | T-Cell Lymphoma of CNS | T Cell Childhood ALL

China
Apollomics (Australia) Pty. Ltd.
Novotech (Australia) Pty Limited; Apollomics Inc. (formerly CBT Pharmaceuticals...

Terminated

APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC

Renal Cell Carcinoma | Hepatocellular Carcinoma

Australia, New Zealand
GlaxoSmithKline

Completed

A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers. (P1A114919)

Multiple Sclerosis, Relapsing-Remitting

Australia
Rhode Island Hospital
amfAR, The Foundation for AIDS Research

Completed

CDC HIV Testing Guidelines: Unresolved Ethical Concerns

HIV Infections

United States
EGEN, Inc.

Terminated

A Study of the Safety and Biological Activity of Intraperitoneal (IP) EGEN-001 Administered Alone and in Combination With Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients

Colorectal Cancer

United States
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393)

Type 2 Diabetes Mellitus

Korea, Republic of
David Bond, MD
Bristol-Myers Squibb

Active, not recruiting

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Mantle Cell Lymphoma | Recurrent Burkitt Lymphoma | Recurrent... and other conditions

United States
CKD Bio Corporation

Completed

Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines

Glabellar Lines

Korea, Republic of

Search clinical trials for: CDC-501

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations